Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in ER+/HER2- Breast Cancer Based on HSD3B1 Genotype
NCT05183828Phase 4Terminated
- Sponsor
- University of Washington
- Start
- Jan 2022
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of letrozole in breast cancer, sponsored by University of Washington. Started Jan 2022; status: terminated.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05183828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183828.